Notably, disruption of HTATSF1–TOPBP1 binding in CK2–HTATSF1–TOPBP1 proficient tumors leads to DNA damage accumulation, breast tumor suppression, and increased sensitivity to chemotherapy. Here, HTATSF1 is linked to breast neoplasm.